1. Home
  2. BIAF vs GRNQ Comparison

BIAF vs GRNQ Comparison

Compare BIAF & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIAF
  • GRNQ
  • Stock Information
  • Founded
  • BIAF 2014
  • GRNQ 2013
  • Country
  • BIAF United States
  • GRNQ Malaysia
  • Employees
  • BIAF N/A
  • GRNQ N/A
  • Industry
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GRNQ EDP Services
  • Sector
  • BIAF Health Care
  • GRNQ Technology
  • Exchange
  • BIAF Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • BIAF 13.0M
  • GRNQ 11.3M
  • IPO Year
  • BIAF 2022
  • GRNQ 2018
  • Fundamental
  • Price
  • BIAF $2.49
  • GRNQ $1.45
  • Analyst Decision
  • BIAF Hold
  • GRNQ
  • Analyst Count
  • BIAF 1
  • GRNQ 0
  • Target Price
  • BIAF N/A
  • GRNQ N/A
  • AVG Volume (30 Days)
  • BIAF 3.3M
  • GRNQ 826.1K
  • Earning Date
  • BIAF 11-13-2025
  • GRNQ 11-12-2025
  • Dividend Yield
  • BIAF N/A
  • GRNQ N/A
  • EPS Growth
  • BIAF N/A
  • GRNQ N/A
  • EPS
  • BIAF N/A
  • GRNQ N/A
  • Revenue
  • BIAF $7,681,059.00
  • GRNQ $3,256,679.00
  • Revenue This Year
  • BIAF N/A
  • GRNQ N/A
  • Revenue Next Year
  • BIAF $20.04
  • GRNQ N/A
  • P/E Ratio
  • BIAF N/A
  • GRNQ N/A
  • Revenue Growth
  • BIAF 4.99
  • GRNQ N/A
  • 52 Week Low
  • BIAF $2.34
  • GRNQ $0.80
  • 52 Week High
  • BIAF $46.53
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • BIAF 46.54
  • GRNQ 51.28
  • Support Level
  • BIAF $2.43
  • GRNQ $1.25
  • Resistance Level
  • BIAF $3.50
  • GRNQ $1.47
  • Average True Range (ATR)
  • BIAF 0.29
  • GRNQ 0.11
  • MACD
  • BIAF -0.09
  • GRNQ -0.00
  • Stochastic Oscillator
  • BIAF 5.69
  • GRNQ 51.28

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: